Curavit Clinical Research officially launches with a focus on virtual trials

Publisher: The Insight Partners

Curavit was founded to help realize the potential of decentralized trials.  Mssrs. Morse and Hanaman come to Curavit with over twenty-five years of experience, founding, building, and running successful technology-enabled healthcare companies.

• The $70 billion global clinical trials market continues to grow, while the success rate of trials continues to decline, often due to lack of enrollment and participation by patients and doctors.
• New technologies and new approaches offer an opportunity to both increase success rates and decrease the costs of traditional clinical trials.
• Virtual clinical trials take advantage of these trends and opportunities.
• Just a small percentage of trials today, virtual trials are projected to increase geometrically due to their advantages.

"Curavit is the result of our desire to solve growing challenges to the important work of drug discovery," said Joel Morse, Chief Executive Officer and Co-Founder of Curavit.  "By combining experience, technology, and solid execution, we will bring cutting-edge research to previously untapped and underserved patient populations."  Chief Commercial Officer and Co-Founder Dave Hanaman added: "We are fortunate to have worked with some of the most respected companies and visionary people in the life sciences industry, and are honored by the support we are receiving from them for this effort."